Podium to Practice: EHA 2025 – Multiple Myeloma: GMMG-CONCEPT TRIAL

Podium to Practice: EHA 2025 – Multiple Myeloma: GMMG-CONCEPT TRIAL

Podium to Practice: EHA 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Donna Reece

Icon Chair Speaker

Speakers

Dr. Irwin Sandhu

Dr. Maria Victoria Mateos Manteca

Studies / Trials Discussed

S209 – ISATUXIMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA-KRD) FOR HIGH-RISK (HR) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): FIRST-TIME REPORT OF THE FULL COHORT OF TRANSPLANT-ELIGIBLE (TE) PATIENTS IN THE GMMG-CONCEPT TRIAL

Studies/trials discussed:

S209 – ISATUXIMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA-KRD) FOR HIGH-RISK (HR) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): FIRST-TIME REPORT OF THE FULL COHORT OF TRANSPLANT-ELIGIBLE (TE) PATIENTS IN THE GMMG-CONCEPT TRIAL
Tagged